Aukje K Mantel-Teeuwisse

List of Publications by Year
in descending order

Version: 2024-02-01

111 papers	2,606 citations	186265 28 h-index	233421 45 g-index
111 all docs	111 docs citations	111 times ranked	3395 citing authors

#	Article	IF	Citations
1	Drug repositioning and repurposing: terminology and definitions in literature. Drug Discovery Today, 2015, 20, 1027-1034.	6.4	229
2	Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union. JAMA - Journal of the American Medical Association, 2008, 300, 1887.	7.4	218
3	Switching from Originator Brand Medicines to Generic Equivalents in Selected Developing Countries: How Much Could Be Saved?. Value in Health, 2012, 15, 664-673.	0.3	122
4	Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico. PLoS ONE, 2013, 8, e75550.	2.5	98
5	Essential Medicines Are More Available than Other Medicines around the Globe. PLoS ONE, 2014, 9, e87576.	2.5	85
6	Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review. BMC Health Services Research, 2019, 19, 536.	2.2	83
7	Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia, 2012, 53, 962-969.	5.1	81
8	Comparison of different methods to estimate prevalence of drug use by using pharmacy records. Journal of Clinical Epidemiology, 2001, 54, 1181-1186.	5.0	73
9	Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases. Drug Safety, 2013, 36, 617-625.	3.2	64
10	Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Nonâ€“Vitamin K Antagonist Oral Anticoagulants. Stroke, 2018, 49, 2122-2128.	2.0	56
11	Evaluation of Post-Authorization Safety Studies in the First Cohort of EU Risk Management Plans at Time of Regulatory Approval. Drug Safety, 2009, 32, 1175-1187.	3.2	46
12	Pharmacovigilance of Biopharmaceuticals. Drug Safety, 2009, 32, 811-817.	3.2	44
13	Characteristics and followâ€up of postmarketing studies of conditionally authorized medicines in the EU. British Journal of Clinical Pharmacology, 2016, 82, 213-226.	2.4	42
14	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 2020, 108, 350-357.	4.7	41
15	Mapping the Safety Profile of Biologicals. Drug Safety, 2010, 33, 865-878.	3.2	40
16	Traceability of biologicals: present challenges in pharmacovigilance. Expert Opinion on Drug Safety, 2015, 14, 63-72.	2.4	37
17	Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. Value in Health, 2020, 23, 10-16.	0.3	37
18	Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f72-f80.	3.0	37

#	Article	IF	Citations
19	Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. Pediatric Diabetes, 2016, 17, 44-52.	2.9	36
20	Essential medicines for COPD and asthma in low and middle-income countries. Thorax, 2014, 69, 1149-1151.	5.6	35
21	Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 684-691.	4.7	34
22	Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy, 2012, 104, 76-83.	3.0	31
23	Rituximabâ€induced thrombocytopenia: a cohort study. European Journal of Haematology, 2012, 89, 256-266.	2.2	31
24	Safety-Related Regulatory Actions for Orphan Drugs in the US and EU. Drug Safety, 2010, 33, 127-137.	3.2	30
25	Seasonal Variation in Penicillin Use in Mexico and Brazil: Analysis of the Impact of Over-the-Counter Restrictions. Antimicrobial Agents and Chemotherapy, 2015, 59, 105-110.	3.2	30
26	Essential medicines for breast cancer in low and middle income countries. BMC Cancer, 2015, 15, 591.	2.6	30
27	Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. Archives of Disease in Childhood, 2015, 100, 763-768.	1.9	29
28	Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. British Journal of Clinical Pharmacology, 2007, 64, 680-685.	2.4	28
29	Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries. Lancet Oncology, The, 2016, 17, e13-e22.	10.7	28
30	Factors influencing non-approval of new drugs in Europe. Nature Reviews Drug Discovery, 2012, 11, 903-904.	46.4	26
31	Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. International Journal for Equity in Health, 2014, 13, 53.	3.5	25
32	Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists. PLoS ONE, 2014, 9, e106072.	2.5	24
33	Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Value in Health, 2021, 24, 759-769.	0.3	24
34	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace, 2021, 23, 1722-1730.	1.7	24
35	Determinants for successful marketing authorisation of orphan medicinal products in the EU. Drug Discovery Today, 2012, 17, 352-358.	6.4	23
36	Judicialization of access to medicines in four Latin American countries: a comparative qualitative analysis. International Journal for Equity in Health, 2019, 18, 68.	3.5	22

#	Article	IF	Citations
37	The Current State of Snakebite Care in Kenya, Uganda, and Zambia: Healthcare Workersâ€™ Perspectives and Knowledge, and Health Facilitiesâ€™ Treatment Capacity. American Journal of Tropical Medicine and Hygiene, 2021, 104, 774-782.	1.4	22
38	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European Heart Journal, 2022, 43, 3528-3538.	2.2	22
39	Extensions of indication throughout the drug product lifecycle: a quantitative analysis. Drug Discovery Today, 2016, 21, 348-355.	6.4	21
40	The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. Pharmacoeconomics, 2021, 39, 1-17.	3.3	21
41	Regulatory Scientific Advice on Non-Inferiority Drug Trials. PLoS ONE, 2013, 8, e74818.	2.5	20
42	Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 8309.	2.6	20
43	Access to sexual and reproductive health commodities in East and Southern Africa: a cross-country comparison of availability, affordability and stock-outs in Kenya, Tanzania, Uganda and Zambia. BMC Public Health, 2020, 20, 1053.	2.9	20
44	Differences in VigiBaseÂ® reporting of aminoglycoside and capreomycinâ€suspected ototoxicity during tuberculosis treatment. Pharmacoepidemiology and Drug Safety, 2017, 26, 1-8.	1.9	18
45	Characteristics of drugs safety signals that predict safety related product information update. Pharmacoepidemiology and Drug Safety, 2018, 27, 789-796.	1.9	18
46	TodayÊ¼s Challenges in Pharmacovigilance. Drug Safety, 2011, 34, 273-287.	3.2	17
47	Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 3-10.	3.0	15
48	Real World Data in Health Technology Assessment of Complex Health Technologies. Frontiers in Pharmacology, 2022, 13, 837302.	3.5	15
49	Drug development for exceptionally rare metabolic diseases: challenging but not impossible. Orphanet Journal of Rare Diseases, 2013, 8, 179.	2.7	14
50	Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study. Frontiers in Pharmacology, 2018, 9, 1243.	3.5	14
51	Compliance of Disease Awareness Campaigns in Printed Dutch Media with National and International Regulatory Guidelines. PLoS ONE, 2014, 9, e106599.	2.5	13
52	Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study. Journal of Pharmaceutical Policy and Practice, 2014, 7, 14.	2.4	13
53	Legal Barriers in Accessing Opioid Medicines: Results of the ATOME Quick Scan of National Legislation of Eastern European Countries. Journal of Pain and Symptom Management, 2014, 48, 1135-1144.	1.2	13
54	Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana. BMC Public Health, 2015, 15, 573.	2.9	12

#	Article	IF	Citations
55	Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries. Addiction, 2017, 112, 1069-1076.	3.3	12
56	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: AÂRetrospective Cohort Study. Clinical Pharmacology and Therapeutics, 2019, 105, 426-435.	4.7	12
57	Population-Based Cohort Study of Anti-Infective Medication Use before and after the Onset of Type 1 Diabetes in Children and Adolescents. Antimicrobial Agents and Chemotherapy, 2014, 58, 4666-4674.	3.2	11
58	Change in parental knowledge, attitudes and practice of antibiotic use after a national intervention programme. European Journal of Public Health, 2018, 28, 724-729.	0.3	11
59	The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health, 2018, 18, 1384.	2.9	11
60	Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discovery Today, 2020, 25, 1223-1231.	6.4	11
61	Regulatory scientific advice in drug development: does company size make a difference?. European Journal of Clinical Pharmacology, 2011, 67, 157-164.	1.9	10
62	Reasons for and Time to Discontinuation of Rimonabant Therapy. Drug Safety, 2012, 35, 1147-1158.	3.2	10
63	Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules. BioDrugs, 2013, 27, 167-174.	4.6	10
64	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. Clinical Pharmacology and Therapeutics, 2020, 107, 287-294.	4.7	10
65	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 2021, 14, 1566-1577.	3.1	10
66	Digital Health in Pharmacy Education: Preparedness and Responsiveness of Pharmacy Programmes. Education Sciences, 2021, 11, 296.	2.6	10
67	Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya. PLoS Neglected Tropical Diseases, 2021, 15, e0009702.	3.0	10
68	Cardiovascular and psychiatric risk profile and patterns of use in patients starting antiâ€obesity drugs. Pharmacoepidemiology and Drug Safety, 2009, 18, 631-638.	1.9	9
69	Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionalsâ€™ preferences. Pharmacology Research and Perspectives, 2021, 9, e00750.	2.4	9
70	The Burden of Snakebite in Rural Communities in Kenya: A Household Survey. American Journal of Tropical Medicine and Hygiene, 2021, 105, 828-836.	1.4	9
71	Reported Challenges in Health Technology Assessment of Complex Health Technologies. Value in Health, 2022, 25, 992-1001.	0.3	9
72	Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USA. Drug Discovery Today, 2016, 21, 536-539.	6.4	8

#	Article	IF	Citations
73	Access to Strong Opioid Analgesics in the Context of Legal and Regulatory Barriers in Eleven Central and Eastern European Countries. Journal of Palliative Medicine, 2018, 21, 963-969.	1.1	8
74	Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovascular Disorders, 2018, 18, 126.	1.7	8
75	Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology, 2020, 86, 1306-1313.	2.4	8
76	Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal. BMC Health Services Research, 2021, 21, 1258.	2.2	8
77	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 2020, , .	0.9	8
78	The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals. European Journal of Clinical Pharmacology, 2013, 69, 217-226.	1.9	7
79	Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil: time series analysis. Health Policy and Planning, 2016, 31, 1291-1296.	2.7	7
80	Systematic reviews of ten pharmaceutical pricing policies â€“ a research protocol. Journal of Pharmaceutical Policy and Practice, 2020, 13, 22.	2.4	7
81	Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart, 2022, 108, 613-618.	2.9	7
82	A comparative human rights analysis of laws and policies for adolescent contraception in Uganda and Kenya. Reproductive Health, 2022, 19, 37.	3.1	7
83	A Cohort Study Exploring Determinants of Safety-Related Regulatory Actions for Biopharmaceuticals. Drug Safety, 2012, 35, 417-427.	3.2	6
84	Towards a theoretical model on medicines as a health need. Social Science and Medicine, 2017, 178, 167-174.	3.8	6
85	The double opioid crisis: A call for balance. Pharmacoepidemiology and Drug Safety, 2019, 28, 1-3.	1.9	6
86	Outcomes of a Postexposure Prophylaxis Program at the Korle-Bu Teaching Hospital in Ghana. Journal of the International Association of Providers of AIDS Care, 2015, 14, 544-552.	1.5	5
87	Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries. Transfusion Medicine Reviews, 2020, 34, 94-100.	2.0	5
88	Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. Journal of Pharmaceutical Policy and Practice, 2021, 14, 18.	2.4	5
89	Preâ€approval and postâ€approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology, 2022, 88, 2169-2179.	2.4	5
90	Four scenarios for the future of medicines and social policy in 2030. Drug Discovery Today, 2022, 27, 2252-2260.	6.4	5

#	Article	IF	Citations
91	Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study. Pharmacoepidemiology and Drug Safety, 2011, 20, 265-271.	1.9	4
92	Future of the <scp>E</scp>uropean <scp>U</scp>nion regulatory network in the context of the uptake of new medicines. British Journal of Clinical Pharmacology, 2013, 76, 1-6.	2.4	4
93	Restoring trust in the pharmaceutical sector on the basis of the SSRI case. Drug Discovery Today, 2014, 19, 523-527.	6.4	4
94	Postâ€marketing dosing changes in the label of biologicals. British Journal of Clinical Pharmacology, 2019, 85, 715-721.	2.4	4
95	The perception of barriers concerning opioid medicines: A survey examining differences between policy makers, healthcare professionals and other stakeholders. Palliative Medicine, 2020, 34, 493-503.	3.1	4
96	Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia. Frontiers in Public Health, 2021, 9, 645499.	2.7	4
97	Disease History and Medication Use as Risk Factors for the Clinical Manifestation of Type 1 Diabetes in Children and Young Adults: An Explorative Case Control Study. PLoS ONE, 2014, 9, e87408.	2.5	4
98	Psychiatric and Cardiovascular Comorbidities in Patients With Diabetes Mellitus Starting Antiobesity Drugs. Obesity, 2008, 16, 2331-2335.	3.0	3
99	Comparing safety information of biosimilars with their originators: a crossâ€sectional analysis of European risk management plans. British Journal of Clinical Pharmacology, 2018, 84, 738-763.	2.4	3
100	Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study. Pharmacy Practice, 2020, 18, 1803.	1.5	3
101	Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle â€“ a focus on benefits and risks. Expert Opinion on Drug Safety, 2021, 20, 1-10.	2.4	3
102	Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care, 2022, 38, e17.	0.5	3
103	A critical review of methodologies used in pharmaceutical pricing policy analyses. Health Policy, 2023, 134, 104576.	3.0	3
104	Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards. BMC Public Health, 2018, 18, 1322.	2.9	2
105	Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability. BMJ Open, 2021, 11, e042948.	1.9	2
106	Understanding innovation of health technology assessment methods: the IHTAM framework. International Journal of Technology Assessment in Health Care, 2022, 38, e16.	0.5	2
107	Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. Pediatric Diabetes, 2018, 19, 121-128.	2.9	1
108	Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e31-e31.	3.0	1

#	Article	IF	Citations
109	Identifying the teaching content on substandard and falsified medical products in global pharmacy education as critical public health issue. Pharmacy Education, 0, , 504-516.	0.6	1
110	Licensing failure in the European decentralised procedure. European Journal of Pharmaceutical Sciences, 2016, 87, 47-51.	4.0	0
111	Comment on â€œDeterministic Sensitivity Analysis Under Ignoranceâ€. Pharmacoeconomics, 2021, 39, 1199-1199.	3.3	0